Abstract:Abstract Background Glycogen storage disease type I(GSDI) is a glucose metabolic disorder caused by glucose-6-phosphatase deficiency. GSDIa patients are characterized by hypoglycemia, hepatomegaly, hyperlipidemia and lactic acidemia. This study aims to review the lipid status in patients with GSDIa, explores the lipid treatment targets and preferable lipid-lowering drugs. Methods The clinical data of GSDIa patients characteristics were collected. Diet control, raw cornstarch were used to maintain normal blood glucose and lipid level. Some patients were given lipid-lowering drugs. We compared the lipid levels before and after each treatment. Results A total of 163 GSDIa patients were enrolled in this study and 773 times of lipid levels were detected. TG was normal in only 13 times of detection from 10 patients(2%). There were 26 patients who took atorvastatin or fibrates (fenofibrate or gemfibrozil) regularly for more than one year. The lipid levels could be improved after lipid-lowering drugs treatment. The therapeutic effect of atorvastatin was better than fibrates. The total cholesterol(TC) was positively correlated with total triglycerides(TG) after treatment. A regression equation was established for TC and TG, TG=-2.86 + 1.63TC. The complication of hyperlipidemia was mainly caused by TC. As long as TC maintained normal, TG did not have to be maintained normal and a certain degree of hypertriglyceridemia can be accepted. The lower bound of China Children's TC abnormal level (5.18 mmol/L) was substituted into the established regression equation to obtain TG = 5.58 mmol/L. We set a target that when the TG level was lower than 5.58 mmol / L after treatment, TC could maintain normally. There was no need for further increasing the dosage of lipid-lowering drug. Conclusion Patients with GSDIa had significant abnormalities in blood lipid metabolism. We found that there was a linear correlation between TC and TG, which was TG=-2.86 + 1.63*TC. We made a point that as long as the TC remained normal, a certain degree of hypertriglyceridemia could be accepted. We set a target that when the TG level was lower than 5.58 mmol / L after treatment, TC could maintain normally. This study found that the therapeutic effect of atorvastatin was better than fibrates.

Medium-Chain Triglyceride Oil and Dietary Intervention Improved Body Composition and Metabolic Parameters in Children with Glycogen Storage Disease Type 1 in Jordan: A Clinical Trial

Medical-Nutritional Intervention in a Jordanian Child with Glycogen Storage Disease Type IIIA: Case Report

Treatment outcomes on growth of children diagnosed with glycogen storage disease presenting to national institute of child health, Karachi, Pakistan.

Clinical and biochemical characteristics of glycogen storage disease in Bangladeshi children from a tertiary care center

Long‐term personalized high‐protein, high‐fat diet in pediatric patients with glycogen storage disease type IIIa: Evaluation of myopathy, metabolic control, physical activity, growth, and dietary compliance

Clinical, biochemical and radiological findings in children with glycogen storage disease.

The lipid Status and linear relationship between TC and TG in Glycogen Storage Disease Ia

Molecular, Biochemical, and Clinical Characterization of Thirteen Patients with Glycogen Storage Disease 1a in Malaysia

Reduced-size liver transplantation for glycogen storage disease.

Glycogen storage disease type III: a mixed-methods study to assess the burden of disease

Personalized management of hepatic glycogen storage disorders: The role of continuous glucose monitoring

Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study

Genetic analysis and long-term treatment monitoring of 11 children with glycogen storage disease type IIIa

PO-0384 The Practical Method To Diagnosis Of Fourteen Cases Of Glycogen Storage Diseases In Our Laboratory

A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III

Intestinal microbiota composition of children with glycogen storage Type I patients

Glycogen storage disease type I: clinical and laboratory profile

A novel nutritional approach to infants and children with congenital diarrhea due to homozygous DGAT1 mutations

A patient with glycogen storage disease type Ia combined with chronic hepatitis B infection: a case report

Glycerol Phenylbutyrate Treatment of 2 Patients With Monocarboxylate Transporter 8 Deficiency

Clinical and genetic features of patients with glycogen storage disease type Ⅸa:An analysis of 20 cases